Zipalertinib plus chemotherapy extends progression‑free survival in EGFR exon 20 NSCLC

A phase III trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer reported that adding zipalertinib to standard platinum‑pemetrexed chemotherapy markedly extended progression‑free survival for patients with advanced non‑small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations. The study enrolled treatment‑naïve participants who received first‑line therapy, comparing the combination regimen with chemotherapy alone.

Results showed a statistically significant improvement in median progression‑free survival for the zipalertinib‑plus‑chemotherapy arm, indicating a potential new standard of care for this molecular subgroup, which historically has responded poorly to existing EGFR inhibitors. The findings underscore the importance of targeted therapies in expanding treatment options for patients with EGFR exon 20 insertion‑positive NSCLC and may influence forthcoming clinical guidelines.